We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.20 | 0.49% | 41.11 | 41.3125 | 40.87 | 40.95 | 2,730,464 | 01:00:00 |
Key strategic priorities
|
Performance Measure
|
Proportion of each award
|
Deliver value to shareholders
|
Total Shareholder Return (TSR)
|
1/3rd
|
Simplify the operating model
|
Adjusted free cash flow
|
1/3rd
|
Deliver more products of value
|
Research & Development (R&D) new product performance
|
1/3rd
|
Performance Level
|
Adjusted Free Cash Flow (£billions)
|
Proportion Vesting
%
|
Below threshold
|
< £ 11.6bn
|
0%
|
Threshold
|
£ 11.6bn
|
25%
|
£ 12.0bn
|
50%
|
|
£ 13.2bn
|
75%
|
|
Maximum
|
£ 13.8bn
|
100%
|
Number of Ordinary Shares/ADS potentially vesting in respect of the element of the award subject to the TSR measure
|
||||
(N.B. One ADS represents two Ordinary Shares)
|
||||
Ordinary Shares
|
6th position or below
|
5th position
|
Maximum
|
|
Sir Andrew Witty*
|
Nil
|
72,168
|
164,017
|
|
Mr S Dingemans*
|
Nil
|
31,755
|
72,171
|
|
Mr R Connor
|
Nil
|
17,268
|
39,244
|
|
Mr N Hirons
|
Nil
|
7,123
|
16,188
|
|
Mr A Hussain
|
Nil
|
34,535
|
78,489
|
|
Mr D Redfern
|
Nil
|
12,519
|
28,452
|
|
Ms C Thomas
|
Nil
|
15,757
|
35,810
|
|
Mr P Thomson
|
Nil
|
9,065
|
20,603
|
|
Dr P Vallance
|
Nil
|
36,694
|
83,394
|
|
Ms E Walmsley
|
Nil
|
29,571
|
67,206
|
|
ADS
|
||||
Dr M Slaoui*
|
Nil
|
23,278
|
52,905
|
|
Mr D Troy
|
Nil
|
14,618
|
33,222
|
|
* Denotes an Executive Director
|
||||
Number of Ordinary Shares/ADS potentially vesting in respect of the element of the award subject to the adjusted free cash flow and R&D new product measures
|
||||
(N.B. One ADS represents two Ordinary Shares)
|
||||
Ordinary Shares
|
Below threshold
|
At threshold
|
Maximum
|
|
Sir Andrew Witty*
|
Nil
|
82,009
|
328,035
|
|
Mr S Dingemans*
|
Nil
|
36,085
|
144,341
|
|
Mr R Connor
|
Nil
|
19,622
|
78,489
|
|
Mr N Hirons
|
Nil
|
8,094
|
32,377
|
|
Mr A Hussain
|
Nil
|
39,245
|
156,978
|
|
Mr D Redfern
|
Nil
|
14,226
|
56,904
|
|
Ms C Thomas
|
Nil
|
17,905
|
71,621
|
|
Mr P Thomson
|
Nil
|
10,302
|
41,207
|
|
Dr P Vallance
|
Nil
|
41,697
|
166,789
|
|
Ms E Walmsley
|
Nil
|
33,603
|
134,412
|
|
ADS
|
||||
Dr M Slaoui*
|
Nil
|
26,452
|
105,809
|
|
Mr D Troy
|
Nil
|
16,611
|
66,445
|
|
* Denotes an Executive Director
|
Number of Ordinary Shares/ADS potentially vesting in respect of the Deferred Bonus Award
|
||
(N.B. One ADS represents two Ordinary Shares)
|
||
Number of Ordinary Shares subject to Deferred Bonus Award
|
Number of ADS subject to Deferred Bonus Award
|
|
Sir Andrew Witty*
|
40,003
|
|
Mr S Dingemans*
|
36,381
|
|
Dr M Slaoui*
|
20,854
|
|
Mr R Connor
|
9,359
|
|
Mr N Hirons
|
13,452
|
|
Mr A Hussain
|
31,788
|
|
Mr D Redfern
|
17,120
|
|
Ms C Thomas
|
25,046
|
|
Mr P Thomson
|
7,662
|
|
Mr D Troy
|
14,760
|
|
Dr P Vallance
|
29,462
|
|
Ms E Walmsley
|
27,549
|
|
* Denotes an Executive Director
|
Number of Ordinary Shares/ADS potentially vesting in respect of the element of the Matching Award subject to the TSR measure
|
|||
(N.B. One ADS represents two Ordinary Shares)
|
|||
Ordinary Shares
|
6th position or below
|
5th position
|
Maximum
|
Sir Andrew Witty*
|
Nil
|
5,867
|
13,334
|
Mr S Dingemans*
|
Nil
|
5,336
|
12,127
|
Mr R Connor
|
Nil
|
1,373
|
3,120
|
Mr N Hirons
|
Nil
|
1,973
|
4,484
|
Mr A Hussain
|
Nil
|
4,662
|
10,596
|
Mr D Redfern
|
Nil
|
2,511
|
5,707
|
Ms C Thomas
|
Nil
|
3,673
|
8,349
|
Mr P Thomson
|
Nil
|
1,124
|
2,554
|
Dr P Vallance
|
Nil
|
4,321
|
9,821
|
Ms E Walmsley
|
Nil
|
4,041
|
9,183
|
ADS
|
|||
Dr M Slaoui*
|
Nil
|
3,059
|
6,951
|
Mr D Troy
|
Nil
|
2,165
|
4,920
|
* Denotes an Executive Director
|
Number of Ordinary Shares/ADS potentially vesting in respect of the element of the Matching Award subject to the adjusted free cash flow and R&D new product measures
|
|||
(N.B. One ADS represents two Ordinary Shares)
|
|||
Ordinary Shares
|
Below threshold
|
At threshold
|
Maximum
|
Sir Andrew Witty*
|
Nil
|
6,667
|
26,669
|
Mr S Dingemans*
|
Nil
|
6,064
|
24,254
|
Mr R Connor
|
Nil
|
1,560
|
6,239
|
Mr N Hirons
|
Nil
|
2,242
|
8,968
|
Mr A Hussain
|
Nil
|
5,298
|
21,192
|
Mr D Redfern
|
Nil
|
2,853
|
11,413
|
Ms C Thomas
|
Nil
|
4,174
|
16,697
|
Mr P Thomson
|
Nil
|
1,277
|
5,108
|
Dr P Vallance
|
Nil
|
4,910
|
19,641
|
Ms E Walmsley
|
Nil
|
4,592
|
18,366
|
ADS
|
|||
Dr M Slaoui*
|
Nil
|
3,476
|
13,903
|
Mr D Troy
|
Nil
|
2,460
|
9,840
|
* Denotes an Executive Director
|
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions